Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says

Executive Summary

Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar
Advertisement

Related Content

Abbott Will Grow Zemplar Sales With Oral Formulation, Pre-dialysis Use
Abbott Will Grow Zemplar Sales With Oral Formulation, Pre-dialysis Use
Sensipar Is $8.10 Per 30 Mg; “Fair Price” For “Major Advance,” Amgen Says
Sensipar Is $8.10 Per 30 Mg; “Fair Price” For “Major Advance,” Amgen Says
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness
Advertisement
UsernamePublicRestriction

Register

PS043543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel